MX347902B - Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma. - Google Patents

Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma.

Info

Publication number
MX347902B
MX347902B MX2014002718A MX2014002718A MX347902B MX 347902 B MX347902 B MX 347902B MX 2014002718 A MX2014002718 A MX 2014002718A MX 2014002718 A MX2014002718 A MX 2014002718A MX 347902 B MX347902 B MX 347902B
Authority
MX
Mexico
Prior art keywords
pain relief
manufacture
composition
same
selective agonist
Prior art date
Application number
MX2014002718A
Other languages
English (en)
Spanish (es)
Other versions
MX2014002718A (es
Inventor
Daniel Bucks
Philip J Birbara
Original Assignee
Vizuri Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vizuri Health Sciences Llc filed Critical Vizuri Health Sciences Llc
Publication of MX2014002718A publication Critical patent/MX2014002718A/es
Publication of MX347902B publication Critical patent/MX347902B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014002718A 2011-09-09 2012-09-10 Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma. MX347902B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533120P 2011-09-09 2011-09-09
US201261642942P 2012-05-04 2012-05-04
PCT/US2012/054511 WO2013036961A1 (en) 2011-09-09 2012-09-10 A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof

Publications (2)

Publication Number Publication Date
MX2014002718A MX2014002718A (es) 2014-08-27
MX347902B true MX347902B (es) 2017-05-18

Family

ID=46940596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002718A MX347902B (es) 2011-09-09 2012-09-10 Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma.

Country Status (9)

Country Link
US (5) US8889659B2 (enExample)
EP (2) EP2753319B1 (enExample)
JP (1) JP6228540B2 (enExample)
KR (1) KR101769010B1 (enExample)
CN (1) CN104010635A (enExample)
BR (1) BR112014005358A8 (enExample)
CA (1) CA2854206C (enExample)
MX (1) MX347902B (enExample)
WO (1) WO2013036961A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769010B1 (ko) * 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도
US20140142073A1 (en) 2012-11-12 2014-05-22 Api Genesis, Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
CA2963570A1 (en) * 2013-10-28 2015-05-07 Atp Institute Pty Ltd Pain relief formulation and method of treatment
ES2874479T3 (es) * 2014-01-23 2021-11-05 Biogaia Ab Agentes que modulan el dolor gastrointestinal
JP6580305B2 (ja) * 2014-03-30 2019-09-25 小林製薬株式会社 外用医薬組成物
JP6599083B2 (ja) * 2014-03-30 2019-10-30 小林製薬株式会社 外用医薬組成物
KR102073258B1 (ko) * 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
KR102413721B1 (ko) * 2014-11-26 2022-06-27 건양대학교산학협력단 통증완화 성분이 포함된 알코올성 조성물, 및 이를 포함하는 알코올 스왑
JP6508671B2 (ja) * 2015-01-30 2019-05-08 ハウスウェルネスフーズ株式会社 トウガラシ抽出物及び／又はショウガ抽出物を含む組成物、ならびにその製造方法
CA2994331C (en) 2015-07-31 2023-10-03 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
FR3039991A1 (fr) * 2015-08-12 2017-02-17 Ab7 Innovation Composition antidouleur comprenant un derive de l'acide salicylique
JP6948762B2 (ja) * 2015-10-16 2021-10-13 株式会社マンダム Ｔｒｐｖ１活性抑制剤作用増幅用組成物
US20190022036A1 (en) * 2016-01-22 2019-01-24 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
CN110300591A (zh) 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
CN110545785A (zh) * 2017-04-04 2019-12-06 花王株式会社 身体化妆品
US20200375915A1 (en) * 2017-04-25 2020-12-03 Srinivas Reddy Male Matrix adhesive patch and process for the preparation thereof
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
MX2020013953A (es) 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
CA3138195A1 (en) 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic compositions
WO2020223093A1 (en) 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic gel compositions
WO2020223092A1 (en) * 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic spray compositions
CN114126605B (zh) 2019-06-11 2023-05-23 先进制药股份有限公司 超氧化物歧化酶可溶性纤维组合物
EP4512472A3 (en) * 2019-08-05 2025-04-30 CS Medica A/S Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
MX2022011400A (es) 2020-03-17 2022-10-13 Gruenenthal Gmbh Aplicacion topica repetida de parche de capsaicina para usarse para tratar pacientes que no responden inicialmente al tratamiento.
AU2021249486B2 (en) 2020-04-03 2025-12-04 Grünenthal GmbH Regimen for repeated topical application of capsaicin patch
CN113662739A (zh) * 2021-08-20 2021-11-19 刘浩泉 一种冰敷贴及其制作方法
AU2023205746A1 (en) * 2022-01-07 2024-07-04 Colgate-Palmolive Company Oral gel compositions
CN114652708B (zh) * 2022-03-07 2024-04-26 宁波奇致年华医疗科技有限公司 一种治疗深部组织疼痛的组合物
CN114917190A (zh) * 2022-06-13 2022-08-19 郑州味千生物技术有限公司 用于掩盖苦味的产品
IL328870A (en) * 2023-12-14 2026-08-01 Vm Therapeutics Llc Topical formulations of calcium channel blockers
KR102956555B1 (ko) * 2026-03-04 2026-04-24 (주) 바이옴에이츠 구강 환경에서의 매운맛 자극 인지에 관여하는 리질락토바실러스 살리바리우스 bz0202 균주 및 이를 포함하는 조성물
KR102956556B1 (ko) * 2026-03-04 2026-04-24 (주) 바이옴에이츠 위장관 환경에서의 매운맛 자극 인지에 관여하는 락티카제이바실러스　람노서스 bz6018 균주 및 이를 포함하는 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486450B1 (en) 1980-07-14 1998-07-28 Joel E Bernstein Method of treating psoriatic skin and composition
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5145675A (en) 1986-03-31 1992-09-08 Advanced Polymer Systems, Inc. Two step method for preparation of controlled release formulations
US4997853A (en) 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5134166A (en) 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
US5135747A (en) * 1991-05-17 1992-08-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Deodorant/antiperspirant products with fragrance and encapsulated odor counteractant
US5178879A (en) 1992-04-17 1993-01-12 Michael Adekunle Capsaicin gel
US5910512A (en) 1994-04-18 1999-06-08 Healthline Laboratories, Inc. Topical analgesic using water soluble capsaicin
US5560910A (en) 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US5665378A (en) * 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
JP3211027B2 (ja) 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
US6573302B1 (en) 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
US6348501B1 (en) 1999-09-29 2002-02-19 Medical Merchandising, Inc. Lotion compositions utilizing capsaicin
JP3989188B2 (ja) * 2001-04-27 2007-10-10 クリストファー・エム・キム 蜂針を用いない蜂毒療法
US20040159575A1 (en) * 2001-12-26 2004-08-19 Jutaro Shudo Access resistant envelope
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
JP5148271B2 (ja) * 2004-06-02 2013-02-20 ニューロジズエックス，インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
CA2602796A1 (en) 2005-04-01 2006-10-12 Neurogesx, Inc. Oils of capsaicinoids and methods of making and using the same
EA200702320A1 (ru) * 2005-04-25 2008-04-28 Ньюроджескс, Инк. Соединения trpv1 агониста и способы их получения и применения
US7282224B1 (en) * 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
EP2200566A1 (en) * 2007-10-11 2010-06-30 McNeil-PPC, Inc. Improved topical pain relief product
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
KR101769010B1 (ko) * 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도

Also Published As

Publication number Publication date
EP3388057A1 (en) 2018-10-17
CA2854206C (en) 2018-04-10
WO2013036961A1 (en) 2013-03-14
KR101769010B1 (ko) 2017-08-17
US8889659B2 (en) 2014-11-18
BR112014005358A8 (pt) 2017-10-03
KR20140062094A (ko) 2014-05-22
US8802736B2 (en) 2014-08-12
US20210100759A1 (en) 2021-04-08
JP2014527964A (ja) 2014-10-23
BR112014005358A2 (pt) 2017-03-28
CA2854206A1 (en) 2013-03-14
US20160106690A1 (en) 2016-04-21
US20130157985A1 (en) 2013-06-20
US20180250246A1 (en) 2018-09-06
EP2753319B1 (en) 2018-04-11
EP3388057B1 (en) 2022-03-09
US20130252925A1 (en) 2013-09-26
JP6228540B2 (ja) 2017-11-08
CN104010635A (zh) 2014-08-27
MX2014002718A (es) 2014-08-27
EP2753319A1 (en) 2014-07-16
US10821088B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
MX377377B (es) Composiciones tópicas para el alivio del dolor, manufactura y uso.
BR112014005358A8 (pt) Composições compreendendo agonista seletivo de trpv1 e seus usos
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
UY35823A (es) Profármacos de antagonista de nmda

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SOLARRESERVE TECHNOLOGY, LLC.

FG Grant or registration